Will the Phase 2 trial "BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma." reach primary completion on or before Aug 7, 2026?

Resolves Yes if ClinicalTrials.gov record NCT06598722 (Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) shows an actual primary completion date on or before Aug 7, 2026. Registered date at generation: Aug 7, 2026.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Aug 7, 2026, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.